Aptuit Inc. is acquiring a pharmaceutical research center in Verona, Italy, from GlaxoSmithKline PLC, with Aptuit continuing to supply Glaxo with research and development services after the transfer.
Greenwich-based Aptuit performs contract R&D and manufacturing services to more than 800 life-science companies in an effort to streamline the drug development process. The company is backed by Welsh, Carson, Anderson & Stowe, a private equity investment firm.
Glaxo announced in February its intent to cease discovery research in select neurosciences areas such as pain and depression, which impacted research at the Verona Medicines Research Centre. The lab has about 500 employees.
ìThis partnership is an example of the developing new model of outsourced R&D collaborations,î said Tim Tyson, CEO of Aptuit, in a prepared statement. ìVerona staff are recognized industry-wide for their drug development expertise.
